Futures
Access hundreds of perpetual contracts
CFD
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Promotions
AI
Gate AI
Your all-in-one conversational AI partner
Gate AI Bot
Use Gate AI directly in your social App
GateClaw
Gate Blue Lobster, ready to go
Gate for AI Agent
AI infrastructure, Gate MCP, Skills, and CLI
Gate Skills Hub
10K+ Skills
From office tasks to trading, the all-in-one skill hub makes AI even more useful.
GateRouter
Smartly choose from 40+ AI models, with 0% extra fees
#TradFi交易分享挑战 Trillion-Dollar Memory
Micron just crashed through the ceiling that separates cyclical chip stocks from structural AI titans. At $971.00 per share and a $1.09 trillion market cap, this former commodity player has transformed into the memory fortress powering every major AI data center on Earth. The 52-week journey from $92.22 to $981.00 is not a rally—it is a complete re-rating of what memory chips are worth in the intelligence age.
🔹 The numbers behind the surge are staggering. Micron posted earnings per share of $21.18, obliterating consensus estimates that had been raised repeatedly throughout the quarter. Revenue guidance for Q3 sits at $33.5 billion, with gross margins exceeding 81%. The company's entire 2026 High Bandwidth Memory supply is already sold out under fixed-price, multi-year contracts—a structural lock on demand that transforms unpredictable cycles into visible, recurring revenue streams.
🔹 The analyst community is scrambling to catch up. Major global banks have revised price targets into the $1,625 to $1,750 range, reflecting a fundamental reassessment of Micron's competitive position. HBM3E and the next-generation HBM4 chips are the essential building blocks for NVIDIA's GPU architectures, and only three global manufacturers can produce them at scale. Among those three, Micron has secured the longest-duration contracts with the largest cloud hyperscalers.
🔹 The transformation from cyclical to structural is now complete. Historically, memory chips experienced violent boom-bust cycles as supply glutted and demand cooled. Those cycles are gone. Fixed-price agreements lock in revenue visibility for years, while capacity constraints ensure pricing power remains firmly with manufacturers. The F/K ratio of 45.84 reflects that the market now values Micron as a growth infrastructure company, not a commodity supplier.
🔹 The broader AI capex supercycle provides the macro tailwind. The five largest cloud providers are projected to spend over $690 billion in 2026 alone, with memory chips consuming a growing share of that budget. AI workloads demand roughly five to seven times more memory than traditional servers. No major new HBM production capacity is expected before 2028, creating a sustained supply-demand imbalance that benefits every player in the memory oligopoly.
A stock that traded at $92 just 52 weeks ago now commands a trillion-dollar valuation and analyst targets above $1,600. The memory chip has become the most critical bottleneck in the AI supply chain, and Micron holds the keys. Are you riding this structural transformation, or watching history repeat itself from the sidelines?
$MU
$971 Chip. $47 Cure.
The chasm between legacy and innovation has never been wider on American exchanges. As May 2026 closes, we are witnessing a brutal divergence: artificial intelligence infrastructure is minting trillion-dollar monarchs, while biotech pioneers scrape the bargain bin. The market is ruthlessly voting for the picks-and-shovels of the A.I. gold rush, and the story is told in the cold, hard prices of these five giants.
🔹 $MU — The Memory Monarch Takes the Crown
Micron crossed the $1 trillion market cap threshold for the first time this week, a historic moment that has analysts scrambling to catch up. The stock is now at $971.00 after smashing earnings estimates by over 40%. The secret? The entire 2026 supply of high-bandwidth memory is sold out. Analysts at MarketWise are now whispering about a $2,500 long-term target, arguing that this is no longer a cyclical stock but a structural A.I. utility.
🔹 #TSM — The Geopolitical Tollbooth
Taiwan Semiconductor sits at $418.45, up a staggering 117% year-over-year and hugging its all-time highs. Owning 72% of the global foundry market, TSMC just raised 3nm prices by 15% and cranked its CapEx to the top of its $56 billion range. You can't build A.I. without chips, and you can't build cutting-edge chips without TSMC. That is not a narrative; it is a geographical monopoly.
🔹 $JNJ — The Quiet Fortress
At $225.46, Johnson & Johnson is doing what defensive giants do: surviving. With a 2.18% dividend yield and a 12% year-to-date rise, it is the adult in the room. While facing the Stelara patent cliff, the MedTech and oncology pipelines are plugging the holes, making this a favorite for those seeking shelter from the tech sector's manic swings.
🔹 $MMM — The Legal Anchor
3M is stuck in the mud at $153.13, weighed down by the PFAS "forever chemicals" legacy in Australia. Despite operational improvements, the stock is down from its February high of $173. Analysts call it a "Hold" with an average target of $172.20, but until the legal fog clears, this is a yield play handcuffed by the past.
🔹 $MRNA — The Pipeline Roulette
Moderna has collapsed to $47.23, a painful fall for the pandemic darling. The COVID cash cow is gone, and the pivot to cancer vaccines and RSV combinations is an expensive bet. The short-term charts are weak. The long-term fate rests entirely on FDA clinical results. This is a high-risk biotech lottery ticket at a deep discount.
The gulf between A.I. hardware and struggling biotech is the defining feature of this market. Micron sells shovels; Moderna searches for miracles. Right now, the crowd is sprinting toward the hardware that builds the future while cautiously watching the science that heals it.
How are you positioning in this extreme divergence—doubling down on the A.I. infrastructure boom, or quietly accumulating the beaten-down innovators waiting for their clinical breakthrough?
⚠️ Not financial advice.